Impaired glutamate transport and glutamate - Glutamine cycling: Downstream effects of the Huntington mutation

Brain

Volumn 125, Issue 8, 2002, Pages 1908-1922

  Behrens, Peter F ^a   Franz, P ^a   Woodman, B ^c   Lindenberg, K S ^b   Landwehrmeyer, G B ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Glutamate transport; Glutamate transporter; Huntington's disease; Mutant huntingtin; Transgenic mouse

Indexed keywords

GLUTAMATE AMMONIA LIGASE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLUTAMINE; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

AGE; AMINO ACID BLOOD LEVEL; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYMPTOM; TRANSGENIC MOUSE;

EID: 0036345741     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf180     Document Type: Article

References (71)

1. Alternative excitotoxic hypotheses
2. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease
3. Astrocyte glutamate transport: Review of properties, regulation, and physiological functions
4. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study
5. Hunting in the calm before the storm
6. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
7. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease
8. Extracellular glutamate and other metabolites in and around RG2 rat glioma: An intracerebral microdialysis study
9. A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system
10. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
11. Distribution of phosphateactivated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in postmortem brain from Huntington's disease and agonal cases
12. Loss of glutamine synthetase activity in the brain in Huntington's disease
13. Regulation of neurotransmitter release by metabotropic glutamate receptors
14. Transcriptional dysregulation in Huntington's disease
15. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
16. Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease
17. Compartmentation of brain glutamate metabolism in neurons and glia
18. Detection of polyglutamine aggregation in mouse models
19. Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism
20. Modulation of human glutamate transporter activity by phorbol ester
21. Regional deafferentiation down-regulates subtypes of glutamate transporter proteins
22. Fimbria-fornix transections selectively down-regulate subtypes of glutamate transporter and glutamate receptor proteins in septum and hippocampus
23. An ultra rapid and sensitive high-performance liquid chromatographic method for determination of tissue and plasma free amino acids
24. Altered striatal neurotransmitter release monitored using microdialysis in Huntington transgenic mice
25. Functional interactions between neurons and astrocytes. I. Turnover and metabolism of putative amino acid transmitters
26. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
27. Taurine in the central nervous system and the mammalian actions of taurine
28. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice
29. Simultaneous isotopic and nonisotopic in situ hybridization histochemistry with cRNA probes
30. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum
31. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease
32. Down-regulation of glial glutamate transporters after glutamatergic denervation in the rat brain
33. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
34. Continuous administration of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylate produces striatal lesion
35. Differential effects of corticostriatal and thalamostriatal deafferentation on expression of the glutamate transporter GLT1 in the rat striatum
36. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1
37. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
38. Lipid metabolism and membrane composition are altered in the brains of type II diabetic mice
39. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
40. Glutamine synthetase: Glial localization in brain
41. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease
42. Glutamate uptake impairment and neuronal damage in young and aged rats in vivo
43. Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: An in vivo microdialysis study
44. Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy
45. Retrieval of cellular mRNA in paraffin-embedded human brain using hydrated autoclaving
46. Post-mortem findings do not suggest a brain glutamine deficiency in Huntington's disease
47. Traumatic brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins in rat brain
48. L-trans-pyrrolidine-2,4-dicarboxylic acidevoked striatal glutamate levels are attenuated by calcium reduction, tetrodotoxin, and glutamate receptor blockade
49. Immunocytochemical localization of cysteine sulfinate decarboxylase in astrocytes in the cerebellum and hippocampus: A quantitative double immunofluorescence study with glial fibrillary acidic protein and S-100 protein
50. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain
51. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation
52. Subtypes of sodium-dependent high-affinity L-[3H]glutamate transport activity: Pharmacologic specificity and regulation by sodium and potassium
53. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis
54. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate
55. Cerebral taurine release mechanisms in vivo: Pharmacological investigations in rats using microdialysis for proof of principle
56. Excitatory amino acid transporters: A family in flux
57. Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: A microdialysis study
58. Neuronal regulation of glutamate transporter subtype expression in astrocytes
59. Biochemical abnormalities and excitotoxicity in Huntington's disease brain
60. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1
61. Immunohistochemical localization of metabotropic glutamate receptors mGluRla and mGluR2/3 in the rat basal ganglia
62. Reduced postischemic expression of a glial glutamate transporter, GLT1, in the rat hippocampus
63. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter
64. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
65. The competitive transport inhibitor L-trans-pyrrolidine-2, 4-dicarboxylate triggers excitotoxicity in rat cortical neuronastrocyte co-cultures via glutamate release rather than uptake inhibition
66. Huntington disease
67. Glutamine, exercise and immune function. Links and possible mechanisms
68. Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-KB
69. Effects of uptake carrier blockers SK & F 89976-A and L-trans-PDC on in vivo release of amino acids in rat hippocampus